Q4 2020 Report and presentation

Tromsø, Norway, 28 January 2021 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 22.1 million (16.3) and an EBITDA of NOK 6.8 million (4.9) for the fourth quarter of 2020. Underlying growth continues. Highlights from Q4 2020 All financials figures are exclusive of discontinued operations (Biotec BetaGlucans) ArcticZymes Technologies had Q4 sales of NOK 22.1 million growing by 35% …

Invitation to presentation of Q4 2020 results

ArcticZymes Technologies presents its report for the fourth quarter 2020 on Thursday, 28. January 2021 at 08.30 a.m. Due to the ongoing situation with spread of coronavirus, a number of measures are being implemented to prevent the spread of infection. These measures are being taken to safeguard the health and security of the Company’s shareholders, employees and other stakeholders, and …

ArcticZymes Technologies announces closing of Biotec BetaGlucans divestment

Tromsø, Norway, 31. December 2020. With reference to announcement made on 14. December 2020, ArcticZymes Technologies ASA (AZT) announces closing of the Biotec BetaGlucans AS divestment. Under the terms of the share purchase agreement (SPA) signed between ArcticZymes Technologies ASA and Lallemand Inc’s subsidiary, Danstar Ferment AG, all closing conditions are fulfilled. In line with the SPA, ArcticZymes Technologies has …

ArcticZymes Technologies divests Biotec BetaGlucans subsidiary to Lallemand

Tromsø, Norway, 14. December 2020. ArcticZymes Technologies ASA (AZT) has today entered into a Share Purchase Agreement (SPA) with Lallemand Inc’s subsidiary, Danstar Ferment AG for the divestment of AZT’s Biotec BetaGlucans AS subsidiary (BBG) The transaction is based on an Enterprise Value of NOK 70 Million payable in cash at closing – expected end of December 2020 and which …